Consun Pharmaceutical Group (SEHK:1681) Could Be 69% Below Fair Value As Valuation Questions Build

Recent scrutiny of Consun Pharmaceutical Group (SEHK:1681) has zeroed in on a puzzle. The stock has enjoyed a strong multi-year run, yet its P/E still sits below much of the pharmaceuticals sector.

Price action has turned lively again for Consun Pharmaceutical Group, with a 20.15% 1‑month share price return and a 15.46% 3‑month share price return suggesting fresh momentum after a flatter year to date. The 1‑year total shareholder return of 10.09% sits on top of a very large 5‑year total shareholder return of more than 5x that frames today’s low P/E debate.

Spot opportunities with a similar profile to Consun Pharmaceutical Group by scanning our hand picked 191 high quality undervalued stocks that pair robust fundamentals with discounted valuations.

Bulls argue Consun Pharmaceutical Group’s recent surge simply reflects solid fundamentals that the market is still underpricing. Bears see a late cycle catch up that masks risk. The valuation numbers start to tip the scales.

Price-to-Earnings of 9.5x: Is it justified?

Valuation arguments around Consun Pharmaceutical Group start with a simple mismatch. The shares last closed at HK$15.68, yet they trade on a P/E of 9.5x while screens point to cheaper pricing than both peers and the wider Hong Kong pharmaceuticals sector.

The P/E ratio compares what you pay for each unit of earnings to what the rest of the market is paying for similar profit streams. For a drug maker that reports net income of CN¥1,175.08m on revenue of CN¥3,633.46m and operates entirely in Mainland China, this yardstick gives you a quick sense of how the market is weighing current profitability against future expectations.

Consun Pharmaceutical Group is flagged as good value relative to peers at a P/E of 9.5x compared with a peer average of 31.1x and the Hong Kong pharmaceuticals industry at 13.8x. The same framework also suggests a fair P/E of 16.4x for the stock, a level the market could move toward if sentiment around its earnings profile and return on equity of 23.4% aligns with this valuation model.

Explore the SWS fair ratio for Consun Pharmaceutical Group.

Result: Price-to-Earnings of 9.5x (UNDERVALUED)

Still, the story around Consun Pharmaceutical Group can change quickly if demand for its Mainland China focused portfolio softens, or if pricing pressure affects key therapies.

Find out about the key risks to this Consun Pharmaceutical Group narrative.

Another view on Consun Pharmaceutical Group’s value

A second lens uses the SWS DCF model, which values Consun Pharmaceutical Group’s future cash flows at HK$51.13 per share against a current price of HK$15.68. That gap points to an undervalued stock on this method. So which signal should carry more weight in your playbook?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Consun Pharmaceutical Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 191 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed signals or a clear tilt one way, you can see the full picture for Consun Pharmaceutical Group by weighing both the positives and the watchpoints yourself. Start with 5 key rewards and 2 important warning signs.

Looking for more ideas beyond Consun Pharmaceutical Group?

If Consun Pharmaceutical Group has sharpened your focus on valuation, broaden your watchlist with a few focused screens that surface different kinds of opportunities.

• Target income first and scan companies offering robust yields and payout histories through the 213 dividend fortresses.
• Hunt for quality marked down on price by filtering for strong fundamentals at attractive valuations with the 618 high quality undiscovered gems.
• Dial up resilience and filter for businesses with sturdier finances and healthier balance sheets using the list of solid balance sheet and fundamentals (203 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com